A resident company of SEZ “Dubna” “PSK Pharma” intends in the near future to start production of two drugs included in the guidelines of the Ministry of health for the prevention of coronavirus infection of officinema and azithromycin, reports the press service of the SEZ “Dubna”.
Officine used for the treatment of rheumatoid arthritis. In methodical recommendations of the Ministry of health it is included as a “drug of proactive anti-inflammatory therapy.”
The broad-spectrum antibiotic azithromycin used in the treatment COVID-19 if there is evidence of adherence to underlying disease bacterial infection.
On the territory of the Russian Federation at the present time was only one drug tofacitinib is Equinus company “Pfizer”. For its production uses of the pharmaceutical substance from Ireland, the production of finished drugs is made in the two courts of the Russian factory “POLYSAN” and the company Pfizer in Germany.
Lyophilized form of azithromycin, which plans to release the “PSK Pharma”, the Russian market has four companies and only one of them – Russian. This is the factory “Biochemist”, located in Mordovia. It uses in the production of Indian pharmaceutical substance.